Press Releases

Formycon AG and its commercialization partner Fresenius Kabi today announced that the European Medicines Agency (“EMA”) has accepted the Marketing Authorization Application (“MAA”) for FYB202, a proposed biosimilar candidate to Stelara®.

Formycon AG today published the financial results and the corporate development of Formycon Group for the first half of 2023.

Formycon AG and its license partner Klinge Biopharma GmbH announce that the U.S. Food and Drug Administration has accepted the biologics license application for FYB203, a biosimilar candidate to Eylea®, for review

Formycon AG today announced details of its financial and earnings conference call for the first half of 2023.

Formycon AG and Fresenius Kabi announced that they have reached a settlement with Johnson & Johnson for the U.S., concerning FYB202

On July 25, 2023, Formycon AG held its regular Annual General Meeting in person in Munich.

Formycon and its license partner Klinge Biopharma GmbH announce that the biologics license application for FYB203 has been submitted to the U.S. Food and Drug Administration in line with the initial schedule.

Formycon presentation at Jefferies Global Healthcare Conference on June 08, 2023 at 14:30 (CET)

Formycon AG today published the unaudited results for the first quarter of the fiscal year 2023.

Formycon AG today announced that members of the Management Board will present at international investor conferences in the second quarter of 2023.

Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today published its financial results and business development for the fiscal year 2022.

Formycon AG today today announced the successful conclusion of the extended Phase I clinical study comparing the pharmacokinetics of FYB202 and the reference drug Stelara®.

Formycon AG today announced that the Company's Supervisory Board has appointed Mr. Enno Spillner to the Company's Executive Board as Chief Financial Officer (CFO) effective April 1, 2023.

Formycon AG today published positive preliminary efficacy and safety data from MAGELLAN-AMD Phase III clinical trial for FYB203, its proposed biosimilar to Eylea®.

Formycon AG as the exclusive owner of the global commercial rights to FYB202, a biosimilar candidate to Stelara® (ustekinumab), announced the conclusion of a global license agreement with Fresenius Kabi AG.

Munich – On the basis of the bookbuilding procedure carried out as part of the private placement, the Management Board, with the approval of the Supervisory Board, set a placement price of EUR 77.00 per new share, resulting in gross proceeds from the offering of EUR 70,070,000.00 before commissions and costs. The New Shares correspond to approximately 6.02% of the Company's currently issued share capital.

Munich – Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) ("Formycon” or “Company") announces that, following strong demand, the Company has decided to upsize their previously announced capital increase from authorized capital from approx. 5% to in total approx. 6% of the outstanding share capital.

Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) intends to issue approx. 5% of the issued share capital of the Company, representing approx. 750,000 new shares (the "New Shares").

Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY), as the exclusive owner of the global commercial rights to FYB202, a biosimilar candidate to Stelara® (ustekinumab), today announced the conclusion of a global license agreement with Fresenius Kabi AG (“Fresenius Kabi”).

Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) announces that Klinge Biopharma GmbH, the exclusive owner of the global commercialization rights of FYB203, Formycon’s biosimilar candidate to Eylea® (aflibercept), has entered into a binding term sheet with Coherus BioSciences, Inc. (“Coherus”) for the exclusive commercialization of FYB203 in the United States (U.S.).